Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer
This is a single center, single arm phase 2 study to establish the safety and efficacy of itacitinib (also known as INCB039110) administered in combination with pembrolizumab in patients with metastatic PD-L1 positive non-small cell lung cancer (NSCLC).
Non Small Cell Lung Cancer
DRUG: Itacitinib|BIOLOGICAL: Pembrolizumab
Number of Subjects With a Response at 12 Weeks According to RECIST 1.1 for the Combination of Pembrolizumab and Itacitinib Among Patients With Previously Untreated, PD-L1 Positive Metastatic NSCLC., Responses will be compared subject's baseline assessment and historical controls using pembrolizumab monotherapy., 12 weeks|Number of Subjects With Toxicities (CTCAE v5.0 Scoring) of Pembrolizumab and Itacitinib in Patients With Previously Untreated, PD-L1 Positive Metastatic NSCLC, Number of subjects treated with the combination., 16 weeks
Number of Participants Who Had a Progression Free Survival (PFS) Treated With Pembrolizumab and Itacitinib., Number of participants who remained progression free at week 12, 12 weeks|Number of Participants Treated With Pembrolizumab and Itacitinib, Who Had a Minimum Duration of Response (DOR) of 12 Weeks., 12 weeks|Overall Survival (OS) for Subjects Treated With Pembrolizumab and Itacitinib., Number of subjects treated with pembrolizumab and itacitinib that survived to week 16., 16 weeks
This is a single center, single arm phase 2 study to establish the safety and efficacy of itacitinib (also known as INCB039110) administered in combination with pembrolizumab in patients with metastatic PD-L1 positive non-small cell lung cancer (NSCLC).